An introduction to GHN Pharma Nordic

Global business in the healthcare eld must be ”Glocal”, in order to reach success. The GHN Group is ”Bridging” three organisations with Global and Local competence. Global Healthcare Network (GHN) a global network of life science specialists that help you find the right competence, in the right place. GHN Pharma Nordic a ”Glocal” Speciality Pharma Company, with priority to original prescription medicines, present in all Nordic countries and GHN Pharma Metabolic specialized in Rare Metabolic Diseases with a local and International precedes.

GHN helping you Globalise – Part 1 Latin America

Under the theme of GHN Helping you Globalise, GHN will highlight a particular region on a monthly basis. The first region will be Latin America a region that is not so well known, but of high potential. This would be followed by other regions. Our local teams in Latin America are ready to support your expansion efforts. We know the complexities and the need for assistance, not in one but in many different areas such as Legal, Regulatory, Medical, Market Access, Distribution, Supply and local follow up.

.

GHN Helping you Globalise – Part 2 Australia and New Zealand

Under the theme of GHN Helping you Globalise, GHN is highlighting particular regions. Welcome to our second edition of Healthy Planet to Healthcare introducing Australia and New Zealand.

CONSIDERING AUSTRALIA & NEW ZEALAND IN YOUR FUTURE STRATEGY? The “Healthy Planet Guide Part 2, Australia & New Zealand”  is the perfect introduction. Read it right here or download it free as a pdf file.

Invest in the GHN Service program including 9 Competence areas.  Define what service you need and PICK YOUR OWN TEAM!  Use the GHN offer of 30 minutes free consultation with our Australian member.

GHN helping you Globalise – Part 3, Singapore & Malaysia

Under the theme of GHN Helping you Globalise, GHN is highlighting particular regions. Welcome to our third edition of Healthy Planet to Healthcare introducing Singapore and Malaysia.

CONSIDERING Singapore & Malaysia IN YOUR FUTURE STRATEGY? Start off by reading the GHN e-Book, “Healthy Planet Part 3, Singapore & Malaysia” or download it free as a pdf file.

Invest in the GHN Service program including 9 Competence areas. Define what service you need and PICK YOUR OWN TEAM! Use the GHN offer of 30 minutes free consultation with our Australian member.

GHN helping you Globalise – Part 4 The Nordics

If you see The Nordic region in your future strategy, read the the GHN eBook, “Healthy Planet, Part 4, The Nordics”  right here or download the book free as a pdf file.

Investing in the Nordic area or introducing new pharmaceutical products in the region can be highly beneficial for pharmaceutical companies due to the following reasons:

1. High-income population: The Nordic countries have a high GDP per capita, and the population has a high purchasing power, making it an attractive market for pharmaceutical products.

2. Advanced healthcare systems: The Nordic countries have well-developed healthcare systems that prioritize patient safety and innovation. This provides a favorable environment for introducing new pharmaceutical products.

3. Favorable regulatory environment: The Nordic countries have a transparent and efficient regulatory framework that prioritizes patient safety while being open to innovation and new technologies.

4. Highly educated and skilled workforce: The Nordic countries have a highly educated and skilled workforce, with a focus on science, technology, engineering, and mathematics (STEM) education.

5. Focus on sustainability and innovation: The Nordic countries prioritize sustainability and innovation, creating a favorable environment for pharmaceutical companies that are committed to developing environmentally sustainable and socially responsible products.

.

Overall, establishing a presence in the Nordic area or introducing new pharmaceutical products in the region can provide access to a high-income population, advanced healthcare systems, a favourable regulatory environment, a highly educated and skilled workforce, and a focus on sustainability and innovation, making it a highly rational argument for pharmaceutical companies to consider.